Enanta Pharmaceuticals Inc. (ENTA) Sees Unusually-High Trading Volume
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) shares saw unusually-high trading volume on Tuesday . Approximately 330,204 shares changed hands during trading, an increase of 5% from the previous session’s volume of 313,375 shares.The stock last traded at $21.27 and had previously closed at $21.97.
Several research analysts have weighed in on the company. Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 12th. Vetr lowered Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $35.45 target price on the stock. in a research report on Monday, April 25th. Finally, JMP Securities lowered Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $28.58.
The company’s 50-day moving average price is $23.26 and its 200 day moving average price is $26.64. The company has a market cap of $404.35 million and a price-to-earnings ratio of 12.54.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, May 9th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.10 by $0.19. The business earned $13 million during the quarter, compared to analysts’ expectations of $16.80 million. During the same quarter in the previous year, the company posted $1.49 EPS. The company’s quarterly revenue was down 77.4% on a year-over-year basis. On average, equities research analysts expect that Enanta Pharmaceuticals Inc. will post $1.00 earnings per share for the current year.
Several hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP raised its stake in shares of Enanta Pharmaceuticals by 44.3% in the fourth quarter. GSA Capital Partners LLP now owns 80,322 shares of the company’s stock worth $2,652,000 after buying an additional 24,670 shares during the period. Schroder Investment Management Group raised its stake in shares of Enanta Pharmaceuticals by 91.8% in the fourth quarter. Schroder Investment Management Group now owns 439,303 shares of the company’s stock worth $14,506,000 after buying an additional 210,303 shares during the period. First Trust Advisors LP purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth approximately $1,374,000. Matarin Capital Management LLC purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth approximately $4,644,000. Finally, Seizert Capital Partners LLC raised its stake in shares of Enanta Pharmaceuticals by 6.0% in the fourth quarter. Seizert Capital Partners LLC now owns 100,151 shares of the company’s stock worth $3,307,000 after buying an additional 5,693 shares during the period.
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.